Business Wire

FDA Grants Marketing Authorization to Banyan Biomarkers for the First Diagnostic Blood Test for Traumatic Brain Injury

Del

Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced that the U.S. Food and Drug Administration (FDA) has granted the De Novo request for the commercialization of Banyan BTITM (Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the evaluation of patients with suspected TBI, also known as concussion. The FDA, in keeping with its commitment to address urgent medical concern of brain injuries, reviewed the test under the Breakthrough Devices Program, which is intended to facilitate the development and expedite the review of innovative breakthrough technologies. Banyan BTI identifies two brain-specific protein biomarkers (Ubiquitin Carboxy-terminal Hydrolase-L1 or UCH-L1 and Glial Fibrilliary Acidic Protein or GFAP) that rapidly appear in the blood after a brain injury, providing objective information to assess patients with suspected mild TBI. The goal of the study was to identify patients with head trauma who could safely forego the need for a CT scan thereby avoiding unnecessary radiation to the brain and reduce costs of care.

“With extensive clinical research and scientific validation, Banyan BTI has shown that these two specific protein biomarkers, which are released from the brain and circulate in the blood after a brain injury, can provide objective data to healthcare providers when evaluating patients with a traumatic brain injury,” said Henry L. Nordhoff, Chairman and CEO of Banyan Biomarkers. “Receiving marketing authorization from the FDA for the first blood test for TBI is a significant milestone that will transform how brain injury is managed. We are honored to have as our partner, the U.S. Department of Defense and the U.S. Army Medical Research and Materiel Command, for supporting the research and development of a diagnostic test that now provides objective quantifiable information to physicians, to eliminate unnecessary CT scans, and guide patient care.”

Automobile accidents, falls, sports-related injuries, assaults, and, in the military, improvised explosive devices (IEDs) and combat wounds are common causes of TBI. The U.S. Center for Disease Control estimates there are more than 2.5 million emergency room visits in the United States as a result of head injuries and TBI is an economic burden of more than $76 billion annually on the healthcare system.1 Traumatic brain injury is the leading cause of disability and the number one cause of death for young adults.2

“The impact of traumatic brain injuries is felt within each branch of the service and throughout the Department of Defense, and were even considered the ‘signature wound’ from recent conflicts,” said Lt. Col. Kara Schmid, Project Manager for the Neurotrauma and Psychological Health Project Management Office for the U.S. Army Medical Materiel Development Activity. “Finding solutions for the diagnosis and evaluation of mild TBI has been a top priority for over a decade now. Obtaining FDA authorization for the first objective blood-based biomarkers of mild TBI is a huge success for the TBI community. This assay will provide a remarkable capability for the way we evaluate and care for our service members with TBI.”

Currently, the CT scan is routinely used to assist physicians in the evaluation of TBI. However, the use of CT scans is highly variable especially in the face of significant trauma with minimal symptoms. Lacking an approved biomarker to guide decision making, the default for physicians was to obtain a CT scan. More than 90 percent of patients presenting to the emergency department with mild TBI or concussion, have a negative CT scan.

“Brain biomarkers will change the practice of emergency care for mild TBI and will greatly assist a large number of patients. The impact will be improved medical care by reducing radiation exposure to the patient and improving efficiency in the emergency department,” stated Andy Jagoda, MD, Professor and Chair in the Department of Emergency Medicine at the Icahn School of Medicine at Mount Sinai.

The FDA granting of the De Novo request for Banyan BTI also creates a classification regulation for devices of this type and permits this diagnostic test to serve as a predicate device. The FDA granting was supported by a prospective multi-center pivotal study. The study called ALERT-TBI, enrolled 2,011 patients at 24 independent clinical sites in the United States and European Union and compared the test's results to head CT scans of patients presenting to emergency departments with suspected head injury. The study showed that Banyan BTI achieved high sensitivity and high NPV (negative predictive value) for ruling out the need for a head CT scan and provides objective data for healthcare providers to aid in the evaluation of patients with suspected TBI. The company is engaged in additional studies to determine if the biomarkers have applications in monitoring recovery after injury as well as their application in other degenerative conditions of the brain.

The development of Banyan BTI TM was supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-10-C-0251. Any views, opinions, conclusions, and/or findings contained in this press release are those of Banyan Biomarkers, Inc. and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

1 CDC  https://www.cdc.gov/traumaticbraininjury/severe.html
2 CDC www.cdc.gov/traumaticbraininjury/get_the_facts.html

About Banyan Biomarkers

Banyan Biomarkers, Inc. has developed the first blood test, Banyan BTI™, that can be used by physicians to objectively aid in the evaluation of patients with suspected traumatic brain injury (TBI), also known as concussions. Banyan BTI consists of two test kits (Banyan UCH-L1® Kit and Banyan GFAP® Kit) that measure two specific protein biomarkers that rapidly appear in the blood after a brain injury. To learn more about the Company and Banyan BTI, visit www.banyanbio.com.

Banyan Biomarkers, Banyan, Brain Trauma Indicator, BTI, Banyan UCH-L1, Banyan GFAP, and the brain and tree logos are the trademarks and copyrights of Banyan Biomarkers, Inc.

Contact information

Banyan Biomarkers, Inc.
Tony Grover
Vice President of Business Development
tgrover@banyanbio.com
+1 (760) 710-0423
or
Little Dog Communications Inc.
Jessica Yingling, Ph.D.
President
jessica@litldog.com
+1 (858) 344-8091

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OnMiners Changing the Game in Cryptocurrency Mining18.3.2019 20:25:00 CETPressemelding

OnMiners S.A (www.onminers.com) has recently earned the distinction becoming the first company ever to introduce an extraordinary range of endothermic cryptocurrency mining rigs. A team of investors working towards making crypto mining simple and profitable, OnMiners has introduced three highly efficient mining rigs utilizing the latest endothermic chip technology. Each of these products offers biggest hash-rates available in the market while minimizing power consumption and heat/noise generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005779/en/ On2U (Photo: Business Wire) The three OnMiners mining rigs named On2U, On4U, and OnTower can mine Bitcoin, Litecoin, Ethereum, Monero, Dash, and Zcash. Users can start mining their preferred coins immediately because all the units come pre-configured and just need to be plugged in. The most noteworthy feature of these mining rigs is their endothermic nature. Unlike any

AGCO Announces Strategic Partnership with Solinftec18.3.2019 19:31:00 CETPressemelding

AGCO Corporation (NYSE:AGCO), a world-leading manufacturer and distributor of agricultural equipment solutions, announces a commercial and technological partnership with Solinftec, a world-leading developer and distributor of digital agriculture solutions. The partnership will give AGCO customers direct access to Solinftec´s portfolio of solutions including on-board computers, weather stations, soil sensors, telemetry networks, proprietary algorithms and the real-time generation of actionable insights generating operational efficiency and agronomic efficacy. The new solutions will launch in Brazil beginning in early 2019 for growers of sugarcane, soybean, corn and cotton and will launch in the United States for the 2020 crop cycle for corn and soybean growers. Solinftec’s offerings will complement the fleet and farm solutions already available through AGCO’s Fuse® smart farming portfolio. For 11 years, Solinftec has brought solutions to its clients that capture and process data real-ti

Epiphany Partners with Konsentus to Advance Open Banking Era18.3.2019 17:00:00 CETPressemelding

Fintech software and solution innovator, Epiphany SRI, today announced a partnership with regtech company, Konsentus. As a result of this partnership, financial organizations will be able to build open digital banking platforms that comply with PSD2 regulations. The deadline for organizations to comply with PSD2 regulations was 14 March 2019. The regulations require legacy banking and financial service providers, that hold online accessible client accounts, to provide Application Programming Interface (API) so that new operators, Third Party Providers (TPP), can develop new services including order placement, payment or account information. The Epiphany Open Digital Banking Platform helps banking and financial organizations remain relevant, and satisfy their customers’ current and future banking needs, by providing access to an ecosystem of advanced financial services. Konsentus is the only live Software as a Service (SaaS) based API solution available to check TPP Identity and Regulat

HubHead Certifies NRX AssetHub 7.0 for Use with SAP NetWeaver®18.3.2019 16:15:00 CETPressemelding

HubHead announces that NRX AssetHub 7.0 has been certified by SAP NetWeaver® 7.3. This SAP certification states that NRX AssetHub 7.0 integrates with SAP NetWeaver and that it complies with all the technical requirements for the SAP certification procedures. This certification means that NRX AssetHub 7.0 can efficiently integrate with SAP® solution environments. NRX AssetHub 7.0 can easily be implemented into SAP® infrastructure, quickly and at a low cost. Dennis Wu, the senior vice president of engineering at HubHead says, “We are excited to receive the SAP NetWeaver certification for the next generation of the NRX AssetHub solution.” HubHead Corp is Sponsoring SAP-Centric EAM: The HubHead team is at SAP-Centric EAM in San Antonio as a Silver Sponsor. SAP-Centric EAM is North America’s only asset management conference powering SAP users. You are encouraged to visit the HubHead team and take advantage of the coffee barista station. A HubHead customer in the oil and gas industry will be

TRIPLE-1, Inc. Signed a Distributorship Contract with Fujitsu Electronics Inc.18.3.2019 15:00:00 CETPressemelding

TRIPLE-1, Inc. (Representative Director: Takuya Yamaguchi) and Fujitsu Electronics Inc. (Representative Director: Junji Ogihara) have entered into a distributorship contract for a mining ASIC (application specific IC) “KAMIKAZE” that uses the world's most advanced 7nm process technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005034/en/ TRIPLE-1 / Fujitsu --- Background: In the development market for mining ICs, which requires huge computing power and high power efficiency, the introduction of advanced process technology has been attempted positively and just like the development market for ICs for smartphones, which is one of the world's leading manufacture industries, the driving force for development came from the process miniaturization in the advanced semiconductor industry. As of 2019, there is a mover away from the mainstream 16nm process which had been the oligopoly of traditional Chinese region manufac

Survey Says: Project Leaders Need More PMTQ18.3.2019 14:00:00 CETPressemelding

Project Management Institute (PMI) today released its Pulse of the Profession® report which reveals that organizations wasted almost 12 percent of their investment in project spend last year due to poor performance—a number that’s barely budged over the past five years. As a solution, PMI is calling on project leaders worldwide to evaluate and bolster their Project Management Technology Quotient or PMTQ. PMI developed the tenets of PMTQ by drawing on insights from innovator companies that put a high priority on digital skills acquisition and knowledge coupled with a commitment to a strong project management culture. PMTQ adds a layer of project management to the concept of technology quotient (TQ), which is defined as a person’s ability to adapt, manage and integrate content advances in technology for a project or organization. "In jobs of the future, project teams will be more and more reliant on technology as either an enabler or sometimes as a team member," said Murat Bicak, Senior